Leerink Partners analyst Richard Newitter maintained a Buy rating on Zimmer Biomet Holdings (NYSE:ZBH) on Wednesday, setting a price target of $196, which is approximately 27.51% above the present share price of $153.71.
Newitter expects Zimmer Biomet Holdings to post earnings per share (EPS) of $0.95 for the third quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Strong Buy rating of shares in Zimmer Biomet Holdings, with an average price target of $193.69.
The analysts price targets range from a high of $210 to a low of $177.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.85 billion and a net profit of $300.8 million. The company's market cap is $32.05 billion.
According to TipRanks.com, Leerink Partners analyst Richard Newitter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 24.0% and a 66.14% success rate.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.